Status and phase
Conditions
Treatments
About
To study the safety, tolerance, and pharmacokinetics of a single dose of bis-POM PMEA (adefovir dipivoxil) when administered by the oral route in patients with HIV infection.
Full description
Five patients are entered at each of three dose levels of bis-POM PMEA administered orally in a single dose.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Prior Medication:
Excluded within 2 weeks prior to study entry:
Excluded within 3 days prior to study entry:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal